Abstract
The positive results obtained with cyclosporine-A both in an experimental model and in selected patients with advanced systemic lupus erythematosus support the hypothesis that the drug could be used as a steroid sparer in the earliest stages of active disease. To determine the 12-month clinical efficacy (disease control and steroid sparing), safety, and tolerability of low-dose cyclosporine-A plus steroids versus steroids alone, we designed a multicenter, open, prospective, randomized, pilot study, controlled for parallel groups. The patients were then followed up to month 24. A total of 18 consenting patients with recently diagnosed systemic lupus erythematosus of moderate severity indicated for the use of steroids in acute boluses and subsequently per os were enrolled at two university hospital medical centers. The protocol was based on three 1-g boluses of 6-methyl-prednisolone followed by cyclosporine-A (<5 mg/kg per day) plus prednisone 0.5–1 mg/kg per day per os, reduced by 5 mg/day every 2 weeks following clinical remission, versus the same doses of oral prednisone alone. The efficacy evaluation was based on a four-point scale (from absent/none to severe) for signs and symptoms of systemic lupus erythematosus and immunoserological parameters. The disease activity index and cumulative prednisone dose per patient were analyzed. Any adverse events were reported. All patients showed a reduction in disease activity index within the 1st month. The results were significantly better in the group with cyclosporine-A plus prednisone throughout month 12 (baseline and 12-month disease activity indexes: 21.3±8.6 and 5.0±2.5 versus 20.4±7.1 and 8.8±6.0 in the prednisone group,P<0.05). The 12-month cumulative mean dose of prednisone was significantly lower in the group with both cyclosporine-A plus prednisone (179.4±40.1 versus 231.8±97.1 mg/kg,P<0.005). No unusual adverse events related to the study drugs have been reported. In particular, renal function and blood pressure monitoring revealed no significant changes from mean baseline values in either group. No disease flares were reported in the group treated with cyclosporine-A plus prednisone during the 12- to 24-month period. Thus cyclosporine-A represents a useful corticosteroid sparer in the maintenance of clinical remission in patients with an early-stage, active systemic lupus erythematosus.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mills JA. Systemic lupus erythematosus. N Engl J Med 1994; 26:1871.
Klippel JH. Systemic lupus erythematosus: treatment related complications superimposed on chronic disease. JAMA 1990; 263:1812.
Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 1995; 7:402.
Krone M, Leonard WJ, Dopper JM, Arya SK, Wong-Staal F, Gallo RC, Waldmann TA, Green WC. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984; 81:5214.
Borel JF. The history of cyclosporine A and its significance. In: White DJG, ed. Cyclosporine A. Amsterdam: Elsevier; 1982:5–17.
Bach JF. Lessons for transplant immunosuppression from the usage of cyclosporine in autoimmune diseases. In: Kahan BD, ed. Cyclosporine: the ten-year experience. Norwalk: Appleton and Lange; 1994:3077–3081.
Blank M, Ben-Bassat M, Shoenfeld Y. The effect of cyclosporin A on early and late stages of experimental lupus. Arthritis Rheum 1992; 35:1350.
Miescher PA, Favre H, Lemoine R, Huang YP. Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 1994; 16:295.
Feutren G, Querin S, Noël LH, Chatenoud L, Beaurain G, Tron F, Lesavre P, Bach JF. Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 1987; III:1063.
Tokuda M, Kurata N, Mizoguchi AJ, Inoh M, Seto K, Kinashi M, Takahara J. Effect of low-dose cyclosporin A on systemic lupus erythematosus. Arthritis Rheum 1994; 37:551.
Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35:669.
Caccavo D, Laganà B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthrits Rheum 1997; 40:27.
Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch M. Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9 [Suppl]:57.
Balletta M, Sabella D, Magri P, Sepe V, Stanziale P, Di Luccio R, Colucci G, Fuiano G. Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992; 99:129.
Hussein MM, Mooÿ JMV, Roujouleh H. Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993; 40:160.
Radhakrishnan J, Kunis CL, D’Agati V, Appel GB. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42:147.
Austin HA, Vaughan EM, Boumpas DT, Klippel JH, Balow JE. Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine A (abstract). Am Soc Nephrol 1996; 7:1328.
Tan EM, Cohen AS, Fries JF, Masi AT, Mc Shane DJ, Rothfield NF, Schaller JR, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271.
Feutren G. The optimal use of cyclosporin A in autoimmune diseases. J Autoimmun 1992; 5 [Suppl A]:193.
Liang MH, Socher SA, Larson MG, Schur PM. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32:1107.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 352:630.
Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31.
Kimberly RP. Corticosteroids and anti-inflammatory drugs. Rheum Dis Clin North Am 1988; 14:203.
Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984; 311:1528.
Panayi GS, Tugwell P. An international consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 23 [Suppl 1]:1.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dammacco, F., Della Casa Alberighi, O., Ferraccioli, G. et al. Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 30, 67–73 (2000). https://doi.org/10.1007/s005990070017
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005990070017